Keros Therapeutics (KROS) Presents At European Hematology Association Congress - Slideshow
Keros Therapeutics(KROS)2020-06-12 18:46| --- | --- | |-----------|-----------------------------------------------------------------------| | | | | | | | | | | Selective | Inhibition of ALK‐2 Signaling Ameliorates Disease in a | | Novel | Model of Iron Refractory Iron Deficiency Anemia (IRIDA) | | | Thomas Backus Natalia Medeiros, Evan Lema, ffolliott | | | , Fisher, Jasbir Seehra, Jennifer Lachey | | | Keros Therapeutics, Lexington MA, USA | | | June 2020 | | | in Focus | | | | | | | Disclosure All listed authors are employees of and shareholder ...